Please Scroll Down to See Forums Below
napsgear
genezapharmateuticals
domestic-supply
puritysourcelabs
UGL OZ
UGFREAK
napsgeargenezapharmateuticals domestic-supplypuritysourcelabsUGL OZUGFREAK

FEMARA vs. LIQUIDEX

johnny tougharms said:
so 2.5 mg of femara is equal to 1mg of dex.....i thought femara was stronger?......what dose of femara is to be used everyday ?????

thats what im thinking:confused: there prolly talking bout the l-dex, i can bet the loot for my next cycle:D
 
johnny tougharms said:
so 2.5 mg of femara is equal to 1mg of dex.....i thought femara was stronger?......what dose of femara is to be used everyday ?????
It depends on what your gear is. It's active for like 50 hrs. I believe, so it can be taken daily or EOD depending on how high your doses are.
 
i did a search on here on femara and it was said that 2.5 mg of femara eod could possibly lower your sperm count and make you sterile...??...any thoughts on that?
 
I don't see the point of using Femara unless you are using a very large amount of Test.

Femara is too strong(and yes that's a problem), Liquidex is much better IMO.
 
Everlast said:
Then technically liquidex is better if you can get by with 1mg eod vs 2.5mg of femera.
Many of you guys are comparing apples to oranges saying ana is better cause you only need 1 mg. Thats like saying dbol is the best cause ya only need 35mg/ed insteald of 100mg/ed of test susp.

When testing products they monitor results of a given product at varying doses. Once they find a dose that gives optimal results and yet going past that point leads to little additional benefit, then that is commonly used dose recommended for its intended purpose.

Now, letrozole is only slightly more expensive than ana and you get 2.5x as much is irrelevant really. What it boils down to is simply the cost of using the product. If your on a cycle and would normally take 1 ana tab eod, then you can take 1 let tab eod and get better results, that is what matters and for those of you who do large cycle and are on the verge of estrogen sides, then let is the way to go.
 
  • Like
Reactions: nbk
Zyglamail said:
Many of you guys are comparing apples to oranges saying ana is better cause you only need 1 mg. Thats like saying dbol is the best cause ya only need 35mg/ed insteald of 100mg/ed of test susp.

When testing products they monitor results of a given product at varying doses. Once they find a dose that gives optimal results and yet going past that point leads to little additional benefit, then that is commonly used dose recommended for its intended purpose.

Now, letrozole is only slightly more expensive than ana and you get 2.5x as much is irrelevant really. What it boils down to is simply the cost of using the product. If your on a cycle and would normally take 1 ana tab eod, then you can take 1 let tab eod and get better results, that is what matters and for those of you who do large cycle and are on the verge of estrogen sides, then let is the way to go.

very well said zyg, do you know if letrozole is a competetive inhibitor or a non-competetive?
 
very well said zyg, do you know if letrozole is a competetive inhibitor or a non-competetive?

Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system.

Here is some more reading with specific number comparisons.

Femara (Letrozole) More Effective Than Arimidex (Anastrozole) at Inhibiting Estrogen in Advanced Breast Cancer


EAST HANOVER, NJ -- January 31, 2002 -- Data from a randomized study examining the ability of Femara® (letrozole) to inhibit total body aromatization and suppress plasma estrogen levels in 12 postmenopausal women with metastatic breast cancer compared to Arimidex® (anastrozole) have been published in the February 2002 issue of the Journal of Clinical Oncology.
The data show that Femara (2.5 mg once daily) more effectively inhibits total body aromatization and suppresses plasma estrogen levels compared to anastrozole (1 mg once daily). The differences between the two drugs in inhibiting total body aromatization (ovaries excepted) were statistically significant as was the suppression of two of the three major estrogens.
"We know that hormone sensitive breast cancers rely on estrogen for growth, and in this study, Femara was shown to be a more effective inhibitor of total body aromatization and suppressor of plasma estrogen levels as compared to anastrozole," said Per Eystein Lonning, MD, professor of oncology, Haukeland University Hospital, Norway.

The primary objective of the study was to compare the effects of the non-steroidal aromatase inhibitors Femara and anastrozole on total body aromatization (the capacity of the whole body to produce estrogens) and plasma estrogen levels.

The trial was a randomized, crossover study of 12 postmenopausal women with metastatic breast cancer whose disease was suitable for treatment with an aromatase inhibitor. Patients were treated sequentially with anastrozole 1 mg followed by Femara 2.5 mg once daily (and vice-versa), each given for six weeks in sequence. Total body aromatization was determined prior to treatment and at the end of each treatment period as were plasma levels of estrone (E1), estradiol (E2) and estrone sulfate (E1S).

The study revealed that whereas on-treatment levels of aromatization were detectable in 11 of 12 patients during treatment with anastrozole (mean percentage inhibition in the whole group 97.3 percent), they were undetectable in all of the 12 patients during treatment with Femara (> 99.1 percent suppression in all patients; Wilcoxon, P = .0022, comparing the two drug regimens).

Treatment with Femara as compared to anastrozole suppressed mean plasma estrogen levels as follows: E1 (84.3 percent versus 81.0 percent), E1S (98.0 percent versus 93.5 percent) and E2 (87.8 percent versus 84.9 percent) respectively. The suppression of plasma levels of E1 and E1S also was found to be better during treatment with Femara compared to anastrozole (P= .019 and P= .0037, respectively). Since the levels of E2 are already very low in postmenopausal women, it was not possible to measure a statistically significant difference for this parameter.

Based on these findings, the authors concluded that Femara is a more effective inhibitor of total body aromatization and suppressor of plasma estrogen levels compared to anastrozole in postmenopausal women with metastatic breast cancer. The clinical relevance of this finding is yet to be determined.

Femara, an aromatase inhibitor, is an oral once-a-day first-line treatment for postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. At the 2001 San Antonio Breast Cancer Symposium, Phase III data were presented demonstrating that Femara may improve survival of postmenopausal women with locally advanced or metastatic breast cancer who are appropriate for hormone therapy, when compared to tamoxifen. The data stemmed from the largest single study ever to evaluate a hormonal therapy in advanced breast cancer.

The U.S. Food and Drug Administration (FDA) approved Femara in the first-line indication in January 2001. Femara is currently available in more than 75 countries worldwide, with first-line approval already gained in more than 50 countries.

Femara is contraindicated in patients with known hypersensitivity to Femara or any of its excipients. Femara is generally well tolerated and adverse reactions rates in the first-line study in which Femara was compared to tamoxifen were similar with those seen in second-line studies.

The most commonly reported adverse events for Femara versus tamoxifen were bone pain (20 percent versus 18 percent), hot flushes (18 percent versus 15 percent), back pain (17 percent versus 17 percent), nausea (15 percent versus 16 percent), dyspnea or labored breathing (14 percent versus 15 percent), arthralgia (14 percent versus 13 percent), fatigue (11 percent versus 11 percent), coughing (11 percent versus 10 percent), constipation (9 percent versus 9 percent), chest pain (8 percent versus 8 percent) and headache (8 percent versus 7 percent).

Femara may cause fetal harm when administered to pregnant women. The incidence of peripheral thromoembolic events, cardiovascular events and cerebrovascular events was less than or equal to 2 percent. There is no clinical experience to date on the use of Femara in combination with other anticancer agents.

SOURCE: Novartis Oncology
 
still need answer

so what would you prefer if you where doing 1 gram of test and dbol, 1.5mg arimidex ED or 2.5mg femera ED
 
I just ordered 2 bottles of letrozole from PNP cause the price was great. The reason I got femera instead of arimidex is because I just thought you get more bang for your buck. I don't take enough AS to use 2.5mg of Fem but I figured that I could take .25cc which is about .625mg EOD and the two bottles I got will last me a long time. I think personally if you can get Femera why bother with Arimidex, just split the doses to what you need and what works for you. They are both great products, they both solve the same problem, they both have the same mechanism sowhy not go with what gives you more bang for your buck. Just my .2 cents
InstantGrowth
 
Re: still need answer

CB38AC said:
so what would you prefer if you where doing 1 gram of test and dbol, 1.5mg arimidex ED or 2.5mg femera ED
If you have taken that much gear before with no problems, stay with anastrozole. If you still bloated and suffered estrogen sides then use letrozole.
 
ok so i guess 2.5mg letrozole is stronger than 1.5mg arim.? I have never done this much gear before but it took .5mg liquidex ED to go with just 500mg test last time....I wanna use whats stronger 100 arim. cost as much as 80 let where i am getting them
 
The thing is, that addition of .5mg of anastrozole will add virtually nothing in regards to effectivness. According to abstacts taking the dose over 1mg offered little if any benefit and why the recommended dose for its intended purpose is 1mg. So in the end, yes, 2.5 let should be more powerfull than 1.5 ana.
 
I thought the main positive effect that Femara has over arimidexis that the femara raises IGF-1 levels where nolvadex and arimidex lowers it???
 
lawnsaver said:
I thought the main positive effect that Femara has over arimidexis that the femara raises IGF-1 levels where nolvadex and arimidex lowers it???
As more digging is done ana definatly appears to lower it. However, depending on which study you look at for letrozole, it either raises it or its unchanged. Either way I feel not lowering it is a plus. Additionally its simply a much more powerfull anti-e. Ive talked to some guys who have used the tabs from a common source and have run some serious cycle abd had no estrogen sides at all.
 
So it would be safe to say that 1.25mg EOD should do the trick!

I think I might give it a shot!

If I dont like it I have a stock pile of arimidex on hand.
 
Its more powerfull but the recommended dose is higher, you need to keep that in mind. 1.25mg letrozole EOD would be equivelent to 1/2 tab (.5mg) ana EOD. So, if you would use 1/2 taba ana EOD on your cycle, then 1/2 tab let EOD should be superior.
 
lawnsaver said:
So could I go .625mg EOD???
I wouldnt try to go any smaller than 1/2 tab eod. Alos, as previously mentioned, if you do fine with ana, then may as well stick with it. Let seems to work better for those who have problems with dbol and/or on very heavy cycles.
 
I am fairly sensitive and I'm a hard gainer. I wanted to get away from a-dex and n-dex which lower IGF-1 levels. I just might try it for shits and giggles.
 
Top Bottom